^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    OncoIndx® Assay

    Company:
    1Cell.AI
    Type:
    Laboratory Developed Test

    Details

    Evidence
    News
    OncoIndx® is a next-generation sequencing (NGS) test designed to support treatment planning for patients with complex, advanced, or treatment-resistant solid tumors. With over 1,000 genes, deep sequencing, and AI-powered reporting, OncoIndx® offers a powerful foundation for personalized oncology, enabling therapeutic decision-making across the entire cancer care journey.
    Cancer:
    Solid Tumor
    Method:
    Next-generation sequencing